Uploaded November 2022 | Updated November 2026, 1 day ago
The goal of cancer medicines is to stop abnormal cells from growing out of control while keeping normal cells as healthy as possible. To do so, scientists can design activity-blocking drugs that bind to highly specific locations on a target protein, like a key that only fits one predetermined keyhole. However, many proteins don’t have the properties needed to create targeted drugs using classic medicinal chemistry approaches. In essence, these proteins are “undruggable” because they lack a keyhole.
Rather than looking for the right key, what if we help cells take out their trash with precision waste disposal, which ‘tags’ a cell as waste to be cleaned up?
This approach, called targeted protein degradation, is still in its early stages, and Novartis is working hard to realize its potential for patients.
Learn more: bit.ly/3Ur1H9c
©2022 Novartis AG
The goal of cancer medicines is to stop abnormal cells from growing out of control while keeping normal cells as healthy as possible. To do so, scientists can design activity-blocking drugs that bind to highly specific locations on a target protein, like a key that only fits one predetermined keyhole. However, many proteins don’t have the properties needed to create targeted drugs using classic medicinal chemistry approaches. In essence, these proteins are “undruggable” because they lack a keyhole.
Rather than looking for the right key, what if we help cells take out their trash with precision waste disposal, which ‘tags’ a cell as waste to be cleaned up?
This approach, called targeted protein degradation, is still in its early stages, and Novartis is working hard to realize its potential for patients.
Learn more: bit.ly/3Ur1H9c
©2022 Novartis AG










